Abstract
Tumor size, axillary lymph node status and expression of steroid receptors are well-established prognostic factors in breast cancer. However, it is not clear if these prognostic factors are time-dependent variables and lose their significance after several years of disease-free survival. To analyse how long these factors keep their prognostic relevance survival of 1162 breast cancer patients was analysed retrospectively. The post-operative follow-up period was split into consecutive 2-year intervals and each interval was analysed for rate of recurrence and rate of tumor depending deaths. Furthermore, a multivariate analysis was performed for the total follow-up time and for the follow-up period starting 5 years after surgery. Multivariate analysis revealed tumor size, axillary lymph node status and estrogen receptor status as independent prognostic parameters. Analysing separately the rate of recurrences and tumor-related deaths during consecutive 2-year intervals, only the tumor size was a constant prognostic parameter, whereas prognostic relevance of lymph node status decreased. Estrogen receptor status associated with favourable prognosis during the first years after surgery changed to an unfavourable prognostic factor 4 years after surgery. To summarize, prognostic factors obtained at the time of surgery can lose their significance with increasing disease-free survival.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Von Kleist S: Prognostic factors in breast cancer: theoretical and clinical aspects. Anticancer Res 16: 3907–3912, 1996
Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jaeger W: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 15: 3669–3674, 2001
Fehm T, Gebauer G, Jaeger W: Clinical utility of serial serum c-erbB-2 determinations in the follow-up of breast cancer patients. Breast Cancer Res Treat 75: 97–106, 2002
Carter CL, Allen C, Henson DE: Relation of tumor size, lymph node status, and survival in 24730 breast cancer cases. Cancer 63: 181–187, 1989
Fisher B, Redmont C, Fisher ER, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic charac-teristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Sur-gical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6: 1076–1087, 1988
McGuire WL, Clark GM, Dressler LG, Owens MA: Role of steroid hormone receptors as prognostic factors in primary breast cancer. NCI Monogr 1: 19–23, 1986
Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, Ferree CR, Muss HB, Green MR, Norton L, Frei III E: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 19: 1205–1211, 1998
Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 re-currences and 24,000 deaths among 75,000 women. Lancet 339: 71–85, 1992
Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK: Significance of axillary lymph node metastasis in primary breast cancer. J Clin Oncol 17: 2334–2340, 1999
Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz Jr AB, Hoehn JL, Lees AW, Dimitrov NV, Bear HD: Effect of preoperative chemotherapy on the out-come of women with operable breast cancer. J Clin Oncol 16: 2672–2685, 1998
McGuire W, Clark GM: Prognostic factors and treatment de-cisions in axillary-node-negative breast cancer. N Engl J Med 326: 1756–1761, 1992
Bundred NJ: Prognostic and predictive factors in breast cancer. Cancer Treat Rev 27: 137–142, 2001
Silvestrini R, Daidone RM, DiFronzo G, Morabito A, Valagussa P, Bonadonna G: Prognostic implication of label-ing index versus estrogen receptors and tumor size in node negative-breast cancer. Breast Canc Res Treat 7: 161–169, 1986
Parl FF, Schmidt BP, Dupont WD, Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, axillary lymph node metastasis, and histopathologic grading. Cancer 54: 2237–2242, 1984
Mansour EG, Gray R, Shatila AH, Osborne CK, Tormey DC, Gilchrist KW, Cooper MR, Falkson G: Efficacy of ad-juvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 320: 485–490, 1990
Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC: Outcome of primary-breast-cancer patients with mi-crometastases: a long-term follow-up study. Lancet 354: 195–200, 1999
Van Trappen PO, Gyselman VG, Lowe DG, Ryan A, Oram DH, Bosze P, Weekes AR, Shepherd JH, Dorudi S, Bustin SA, Jacobs IJ: Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet 357: 15–20, 2001
Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G: Cytokeratin-positive cells in bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342: 525–533, 2000
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gebauer, G., Fehm, T., Lang, N. et al. Tumor Size, Axillary Lymph Node Status and Steroid Receptor Expression in Breast Cancer: Prognostic Relevance 5 Years after Surgery. Breast Cancer Res Treat 75, 167–173 (2002). https://doi.org/10.1023/A:1019601928290
Issue Date:
DOI: https://doi.org/10.1023/A:1019601928290